---
title: "Lixte Biotechnology Holdings 10-K: $0 Revenue, $(1.26) EPS"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281232249.md"
description: "Lixte Biotechnology Holdings reported no revenue for 2025, with a net loss of $6.01 million and a loss per share of $(1.26). The company continues to invest in clinical programs despite no commercial sales, focusing on equity financings to support ongoing trials. Key developments include advancements in LB-100 trials, acquisition of Liora Technologies Europe, and partnerships with major institutions. Management emphasizes the need for funding amid uncertainty regarding the company's ability to continue operations."
datetime: "2026-03-31T19:15:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281232249.md)
  - [en](https://longbridge.com/en/news/281232249.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281232249.md)
---

# Lixte Biotechnology Holdings 10-K: $0 Revenue, $(1.26) EPS

Lixte Biotechnology Holdings reported no revenues for the year ended December 31, 2025 and posted a net loss of $6.01 million, resulting in net loss per common share of $(1.26). The company recorded a loss from operations of $5.11 million for 2025, reflecting continued investment in clinical programs and strategic assets despite no commercial sales. Management highlighted a focus on equity financings to support ongoing trials and recommissioning of acquired proton prototype assets amid going-concern uncertainty.

**Financial Highlights**

-   **Revenues:** $0 for the years ended December 31, 2025 and 2024.
-   **Operating Income (Loss):** Loss from operations of $(5,107,621) for 2025.
-   **Net Income (Loss):** Net loss of $(6,009,520) for 2025.
-   **Net Income Per Share:** Net loss per common share – basic and diluted of $(1.26) for 2025.

**Business Highlights**

-   **Clinical Development:** Continued advancement of LB-100 in multiple Phase 1b/2 trials including ovarian clear cell, MSS colorectal cancer, and soft tissue sarcoma, with site expansions and ongoing dosing.
-   **Regulatory & Safety Events:** Two serious adverse events in the colorectal trial prompted an IRB review and a temporary hold; the trial was reinstated and enrollment has resumed.
-   **Strategic Asset Addition:** Acquired a majority stake in Liora Technologies Europe and the LiGHT proton prototype; plans include approximately $2.0 million for recommissioning and positioning the prototype as an IP-rich asset.
-   **Partnerships & Collaborations:** Collaborations with MD Anderson, NKI, GEIS and an arrangement with GSK for drug supply and combination immunotherapy studies supporting trial execution.
-   **Operational Funding Focus:** Management is prioritizing equity financings to fund ongoing clinical trials and LiGHT recommissioning amid material uncertainty about the company's ability to continue as a going concern.

Original SEC Filing: LIXTE BIOTECHNOLOGY HOLDINGS, INC. \[ LIXT \] - 10-K - Mar. 31, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [LIXT.US](https://longbridge.com/en/quote/LIXT.US.md)

## Related News & Research

- [Cardiff Oncology updates Phase 2 onvansertib data in first-line RAS-mutated mCRC trial](https://longbridge.com/en/news/287272648.md)
- [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md)
- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)
- [Bristol-Myers Squibb-Anthropic AI Deal Targets Faster Drug Discovery](https://longbridge.com/en/news/287100303.md)
- [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md)